 Vibha Sharma
Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 11 | 2023 | 350 | 1.070 |
Why?
| | Retinoid X Receptors | 7 | 2011 | 38 | 0.550 |
Why?
| | Deep Brain Stimulation | 1 | 2021 | 219 | 0.540 |
Why?
| | Paraparesis | 1 | 2016 | 7 | 0.490 |
Why?
| | Injections, Epidural | 1 | 2016 | 28 | 0.490 |
Why?
| | Arteriovenous Fistula | 1 | 2016 | 38 | 0.470 |
Why?
| | Retinoids | 5 | 2011 | 33 | 0.470 |
Why?
| | Embolization, Therapeutic | 1 | 2016 | 242 | 0.400 |
Why?
| | Telemedicine | 1 | 2021 | 961 | 0.350 |
Why?
| | Thyroid Gland | 3 | 2011 | 89 | 0.350 |
Why?
| | Thyroid Carcinoma, Anaplastic | 2 | 2023 | 36 | 0.330 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 55 | 0.320 |
Why?
| | Calcitriol | 1 | 2010 | 57 | 0.320 |
Why?
| | Pituitary Gland | 2 | 2011 | 149 | 0.300 |
Why?
| | Hypothalamus | 2 | 2011 | 163 | 0.290 |
Why?
| | Receptors, Retinoic Acid | 3 | 2004 | 42 | 0.270 |
Why?
| | High-Intensity Focused Ultrasound Ablation | 1 | 2025 | 13 | 0.220 |
Why?
| | Urea | 1 | 2023 | 85 | 0.190 |
Why?
| | Carcinoma | 3 | 2009 | 225 | 0.190 |
Why?
| | Cell Line, Tumor | 11 | 2019 | 3542 | 0.180 |
Why?
| | Piperidines | 1 | 2023 | 222 | 0.180 |
Why?
| | Psychotic Disorders | 1 | 2023 | 189 | 0.170 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2023 | 223 | 0.170 |
Why?
| | Remote Consultation | 1 | 2021 | 66 | 0.160 |
Why?
| | Dementia | 1 | 2023 | 327 | 0.150 |
Why?
| | Peanut Hypersensitivity | 1 | 2020 | 143 | 0.140 |
Why?
| | Focal Adhesion Kinase 1 | 2 | 2016 | 32 | 0.140 |
Why?
| | Gene Expression | 1 | 2004 | 1476 | 0.140 |
Why?
| | Adenocarcinoma, Follicular | 1 | 2019 | 40 | 0.140 |
Why?
| | Transcription Factors | 2 | 2004 | 1734 | 0.140 |
Why?
| | Adrenal Cortex | 1 | 2018 | 33 | 0.130 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 254 | 0.130 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 41 | 0.130 |
Why?
| | Alzheimer Disease | 1 | 2023 | 630 | 0.130 |
Why?
| | Parkinson Disease | 1 | 2023 | 599 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2014 | 977 | 0.130 |
Why?
| | Benzoates | 3 | 2009 | 49 | 0.130 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2019 | 212 | 0.120 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2018 | 70 | 0.120 |
Why?
| | Adrenocortical Carcinoma | 1 | 2018 | 72 | 0.120 |
Why?
| | Thiazolidinediones | 2 | 2009 | 139 | 0.120 |
Why?
| | Thoracic Vertebrae | 1 | 2016 | 82 | 0.120 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2019 | 431 | 0.110 |
Why?
| | Antineoplastic Agents | 4 | 2012 | 2214 | 0.100 |
Why?
| | Genes, Tumor Suppressor | 1 | 2014 | 85 | 0.100 |
Why?
| | Pandemics | 1 | 2021 | 1707 | 0.090 |
Why?
| | src-Family Kinases | 1 | 2012 | 92 | 0.090 |
Why?
| | Thiazoles | 1 | 2012 | 141 | 0.090 |
Why?
| | Tetrahydronaphthalenes | 2 | 2009 | 31 | 0.080 |
Why?
| | Humans | 18 | 2025 | 145475 | 0.080 |
Why?
| | Deoxyribonucleases, Type II Site-Specific | 1 | 2010 | 13 | 0.080 |
Why?
| | Steroid Hydroxylases | 1 | 2010 | 19 | 0.080 |
Why?
| | Cell Survival | 2 | 2012 | 1100 | 0.080 |
Why?
| | Vitamin D3 24-Hydroxylase | 1 | 2010 | 16 | 0.080 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2010 | 18 | 0.080 |
Why?
| | Blotting, Western | 3 | 2014 | 1179 | 0.080 |
Why?
| | Thyroxine | 2 | 2011 | 66 | 0.080 |
Why?
| | Carrier Proteins | 1 | 2014 | 728 | 0.080 |
Why?
| | MAP Kinase Kinase 2 | 1 | 2009 | 28 | 0.070 |
Why?
| | Bone Neoplasms | 1 | 2012 | 259 | 0.070 |
Why?
| | Cell Proliferation | 6 | 2019 | 2507 | 0.070 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2009 | 70 | 0.070 |
Why?
| | Proto-Oncogene Proteins pp60(c-src) | 1 | 2009 | 14 | 0.070 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2009 | 35 | 0.070 |
Why?
| | Dasatinib | 2 | 2023 | 58 | 0.070 |
Why?
| | Mice | 9 | 2019 | 18329 | 0.070 |
Why?
| | Carcinoma, Papillary | 1 | 2009 | 77 | 0.070 |
Why?
| | Pyrimidines | 1 | 2012 | 530 | 0.070 |
Why?
| | RNA, Messenger | 3 | 2005 | 2803 | 0.070 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2010 | 881 | 0.070 |
Why?
| | Polymorphism, Genetic | 1 | 2010 | 614 | 0.070 |
Why?
| | PPAR gamma | 2 | 2009 | 178 | 0.070 |
Why?
| | Quinazolines | 1 | 2009 | 266 | 0.060 |
Why?
| | MAP Kinase Signaling System | 1 | 2009 | 307 | 0.060 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2009 | 207 | 0.060 |
Why?
| | Benzodioxoles | 1 | 2009 | 161 | 0.060 |
Why?
| | Vitamin D | 1 | 2010 | 403 | 0.060 |
Why?
| | Base Sequence | 1 | 2010 | 2170 | 0.060 |
Why?
| | Mice, Nude | 3 | 2016 | 679 | 0.060 |
Why?
| | Tumor Cells, Cultured | 2 | 2009 | 886 | 0.060 |
Why?
| | Iodide Peroxidase | 1 | 2005 | 35 | 0.060 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2005 | 139 | 0.060 |
Why?
| | Thyrotropin | 1 | 2005 | 120 | 0.060 |
Why?
| | Magnetic Resonance Imaging, Interventional | 1 | 2025 | 30 | 0.050 |
Why?
| | Retinoid X Receptor gamma | 1 | 2004 | 4 | 0.050 |
Why?
| | Heterografts | 2 | 2016 | 143 | 0.050 |
Why?
| | Essential Tremor | 1 | 2025 | 24 | 0.050 |
Why?
| | Organic Chemicals | 1 | 2005 | 112 | 0.050 |
Why?
| | Lipoprotein Lipase | 1 | 2004 | 56 | 0.050 |
Why?
| | Mutation | 2 | 2019 | 4075 | 0.050 |
Why?
| | Surgery, Computer-Assisted | 1 | 2025 | 85 | 0.050 |
Why?
| | Animals | 9 | 2019 | 38030 | 0.050 |
Why?
| | Transfection | 1 | 2005 | 926 | 0.050 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2009 | 1443 | 0.050 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2023 | 108 | 0.050 |
Why?
| | Apoptosis | 3 | 2012 | 2440 | 0.050 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2012 | 934 | 0.050 |
Why?
| | Protein Isoforms | 1 | 2004 | 397 | 0.050 |
Why?
| | Melanoma | 1 | 2009 | 759 | 0.040 |
Why?
| | Cell Division | 1 | 2004 | 756 | 0.040 |
Why?
| | Dietary Fats | 1 | 2004 | 308 | 0.040 |
Why?
| | Middle Aged | 3 | 2023 | 36215 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 2028 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2023 | 440 | 0.040 |
Why?
| | Treatment Outcome | 1 | 2016 | 11772 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2005 | 1246 | 0.040 |
Why?
| | Cell Cycle | 1 | 2004 | 598 | 0.040 |
Why?
| | Male | 5 | 2023 | 72843 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2005 | 2188 | 0.040 |
Why?
| | Recurrence | 1 | 2023 | 1138 | 0.040 |
Why?
| | Cell Line | 1 | 2005 | 2823 | 0.040 |
Why?
| | Desensitization, Immunologic | 1 | 2020 | 89 | 0.040 |
Why?
| | Arachis | 1 | 2020 | 108 | 0.040 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2014 | 749 | 0.040 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 1963 | 0.040 |
Why?
| | Neoplasm Transplantation | 1 | 2019 | 246 | 0.030 |
Why?
| | Administration, Oral | 1 | 2020 | 866 | 0.030 |
Why?
| | Aldosterone | 1 | 2018 | 42 | 0.030 |
Why?
| | Allergens | 1 | 2020 | 386 | 0.030 |
Why?
| | Liver | 1 | 2005 | 1896 | 0.030 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 176 | 0.030 |
Why?
| | Cell Growth Processes | 1 | 2016 | 48 | 0.030 |
Why?
| | Phosphorylation | 2 | 2012 | 1707 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2020 | 2062 | 0.030 |
Why?
| | Signal Transduction | 3 | 2016 | 5216 | 0.030 |
Why?
| | Ligands | 2 | 2009 | 665 | 0.030 |
Why?
| | Time Factors | 1 | 2005 | 7123 | 0.030 |
Why?
| | Carcinogenesis | 1 | 2016 | 228 | 0.030 |
Why?
| | Muscle, Skeletal | 1 | 2004 | 1789 | 0.020 |
Why?
| | Transduction, Genetic | 1 | 2014 | 132 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2016 | 688 | 0.020 |
Why?
| | Cell Cycle Checkpoints | 1 | 2012 | 97 | 0.020 |
Why?
| | Thyrotropin, beta Subunit | 1 | 2011 | 5 | 0.020 |
Why?
| | Glycoprotein Hormones, alpha Subunit | 1 | 2011 | 23 | 0.020 |
Why?
| | Aged | 2 | 2023 | 26153 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2023 | 8333 | 0.020 |
Why?
| | Mice, 129 Strain | 1 | 2011 | 84 | 0.020 |
Why?
| | Tumor Burden | 1 | 2012 | 325 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2014 | 1716 | 0.020 |
Why?
| | Butadienes | 1 | 2009 | 33 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2012 | 471 | 0.020 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2009 | 194 | 0.020 |
Why?
| | Benzamides | 1 | 2009 | 226 | 0.020 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2009 | 196 | 0.020 |
Why?
| | Nitriles | 1 | 2009 | 207 | 0.020 |
Why?
| | Female | 3 | 2023 | 78845 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2009 | 762 | 0.020 |
Why?
| | United States | 1 | 2025 | 16098 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2009 | 637 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2009 | 372 | 0.010 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 820 | 0.010 |
Why?
| | Drug Delivery Systems | 1 | 2009 | 381 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2011 | 1454 | 0.010 |
Why?
| | Luciferases | 1 | 2004 | 153 | 0.010 |
Why?
| | Immunoprecipitation | 1 | 2004 | 148 | 0.010 |
Why?
| | Protein Binding | 1 | 2009 | 2238 | 0.010 |
Why?
| | Protein Kinase Inhibitors | 1 | 2009 | 981 | 0.010 |
Why?
| | Adolescent | 1 | 2020 | 22530 | 0.010 |
Why?
| | Child | 1 | 2020 | 22707 | 0.010 |
Why?
| | Weight Gain | 1 | 2004 | 561 | 0.010 |
Why?
|
|
Sharma's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|